Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
We studied the effect of intravenous infusion of synthetic truncated GLP-1 (proglucagon 78-107-amide) on fasting and postprandial gastric acid secretion, gastric emptying, and pancreatic secretion of trypsin and lipase in eight normal volunteers using marker dilution and aspiration technique. The infusion resulted in a plasma concentration of 110 +/- 14 pmol/liter (mean +/- SEM). Truncated GLP-1 significantly inhibited postprandial acid secretion by 43 +/- 11% in spite of unchanged plasma gastrin concentration. Gastric emptying rate decreased significantly; 50% emptying time increased from 16 +/- 2 min to 30 +/- 5 min. Postprandial trypsin and lipase outputs were significantly inhibited by 47 +/- 17% and 40 +/- 9% during truncated GLP-1 infusion. Pancreatic enzyme output was linearly correlated to gastric emptying, and truncated GLP-1 did not affect this relationship, suggesting that the effect on pancreatic secretion was secondary to the effect on gastric emptying. Postprandial insulin and glucagon concentrations were similar with and without truncated GLP-1 infusion in spite of significantly lower blood glucose levels (5.2 +/- 0.2 versus 3.7 +/- 0.3), indicating that GLP-1 stimulated insulin secretion and inhibited glucagon secretion. In conclusion, our results suggest that truncated GLP-1 act as a physiological inhibitor of gastric and pancreatic functions in man.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In particular, GLP-1R agonism not only emerged as a powerful tool in the treatment of T2D and excess adiposity56, but also displayed favorable effects on the cardiovascular system57 and neurodegenerative diseases55.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [57]
In the citing paper
“GLP-1 has been shown to inhibit glucagon secretion and slow gastric emptying.5, 6”
Citations
Cites
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Physiology of the Gastrointestinal Tract
Ouyang, A. (1988) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1988.03410100162049 · Cited by 950
Mojsov, S., Weir, G. C., & Habener, J. F. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112855 · Cited by 882
Gutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868
Self-citationMojsov, S., Heinrich, G., Wilson, I. B., Ravazzola, M., Orci, L., & Habener, J. F. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67324-7 · Cited by 724
Albano, J. D. M., Ekins, R. P., Maritz, G., & Turner, R. C. (1972) · Acta Endocrinologica · doi:10.1530/acta.0.0700487 · Cited by 620
Truncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gut
Holst, J. J., Ørskov, C., Vagn Nielsen, O., & Schwartz, T. W. (1987) · FEBS Letters · doi:10.1016/0014-5793(87)81430-8 · Cited by 615
Self-citationØRSKOV, C., HOLST, J. J., KNUHTSEN, S., BALDISSERA, F. G. A., POULSEN, S. S., & NIELSEN, O. V. (1986) · Endocrinology · doi:10.1210/endo-119-4-1467 · Cited by 482
Self-citationØRSKOV, C., HOLST, J. J., & NIELSEN, O. V. (1988) · Endocrinology · doi:10.1210/endo-123-4-2009 · Cited by 396
Self-citationOrskov, C., Jeppesen, J., Madsbad, S., & Holst, J. J. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115012 · Cited by 378
Self-citation
Research works printed but not linked: 4
- Holst JJ: Enteroglucagon. Adv Metab Dis 11:392?419, 1988
- Dimagno EP: Alternations and consequences of interdigestive and poststimulatory human exocrine pancreatic secretion in health and disease. Scand J Gastroenterol 12(suppl 87): 69, 1983
- Holst JJ, Creutzfeldt M, Holm G, Jensen E, Poulsen D, Sparsø B, Schmidt A: Persistent glucagonemia after pancreatectomy in pigs. Diabete Metab 4:75?79, 1978
- Solomon TE: Control of exocrine pancreatic secretion.In Physiology of the Gastrointestinal Tract, 2nd ed. LR Johnson (ed). New York, Raven Press, 1987, pp 1173?1208
Cited by
Items 501–600 of 687
Jalleh, R. J., Wu, T., Umapathysivam, M. M., Young, R. L., Jones, K. L., Marathe, C. S., Rayner, C. K., Plummer, M. P., & Horowitz, M. (2026) · Physiological Reviews · doi:10.1152/physrev.00009.2025 · Cited by 6
Pal, B., & Chattopadhyay, M. (2024) · Journal of Diabetology · doi:10.4103/jod.jod_117_23 · Cited by 8
Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Diamant, M., den Bos, I. C. P.-V., van Raalte, D. H., & Cahen, D. L. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12612 · Cited by 7
Carlin, S., Kennelly, J. P., Fedoruk, H., Quiroga, A. D., Leonard, K., Nelson, R., Thiesen, A., Buteau, J., Lehner, R. S., & Jacobs, R. L. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2021.159109 · Cited by 8
Incretins in the ICU: is insulin on its way out?
Kovalaske, M. A., & Gandhi, G. Y. (2009) · Critical Care · doi:10.1186/cc7913 · Cited by 6
Discovery of novel DPP IV inhibitors: application of pharmacophore-based virtual screening
Sharma, J. N., Yadav, D., & Paliwal, S. (2012) · Medicinal Chemistry Research · doi:10.1007/s00044-012-0044-8 · Cited by 6
Nagai, Y., Mukai, K., Otsuki, M., Kimura, T., Kozawa, J., Nishizawa, H., Maeda, N., Matsuoka, T., Iwahashi, H., Imagawa, A., et al. (2018) · Internal Medicine · doi:10.2169/internalmedicine.1585-18 · Cited by 7
The homeostatic dynamics of feeding behaviour identify novel mechanisms of anorectic agents
McGrath, T., Spreckley, E., Rodriguez, A. F., Viscomi, C. F., Alamshah, A., Akalestou, E., Murphy, K. G., & Jones, N. S. (2019) · PLoS Biology · doi:10.1371/journal.pbio.3000482 · Cited by 7
Molecular dynamic simulations reveal the mechanism of binding between xanthine inhibitors and DPP-4
Gu, Y., Wang, W., Zhu, X., & Dong, K. (2014) · Journal of Molecular Modeling · doi:10.1007/s00894-014-2075-1 · Cited by 7
Intestinal Transit of Chyme and its Regulatory Role: Clinical Implications
Layer, P., & Keller, J. (1999) · Springer eBooks · doi:10.1007/978-3-642-60068-5_11 · Cited by 6
Nagell, C. F., Pedersen, J. F., & Holst, J. J. (2006) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520600780262 · Cited by 7
Self-citationWatkins, J. D., Smith, H., Hengist, A., Brunsgaard, L. H., Mikkelsen, U. R., Koumanov, F., Betts, J. A., & Gonzalez, J. T. (2021) · British Journal Of Nutrition · doi:10.1017/s000711452100297x · Cited by 5
Kilari, E. K., Putta, S., & Silakabattini, K. (2020) · Indian Journal of Pharmaceutical Education and Research · doi:10.5530/ijper.54.2s.84 · Cited by 5
Manell, E., Puuvuori, E., Svensson, A. C., Velikyan, I., Hulsart‐Billström, G., Hedenqvist, P., Holst, J. J., Jensen‐Waern, M., & Eriksson, O. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-002083 · Cited by 11
Self-citationThe use of liraglutide, a GLP-1 agonist, in obese people with type 1 diabetes
Gillani, S. M. R., & Singh, B. M. (2014) · The British Journal of Diabetes · doi:10.15277/bjdvd.2014.022 · Cited by 5
GLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly?
Whitehead, J. P., Taing, M., & Rose, F. J. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s35723 · Cited by 11
Doggrell, S. A. (2007) · Reviews on Recent Clinical Trials · doi:10.2174/157488707779318053 · Cited by 5
Martin, C. L. (2008) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721708319238 · Cited by 5
Li, J., Wang, S., Zhang, N., Li, Z., Li, R. Q., & Li, C. (2010) · British Journal Of Nutrition · doi:10.1017/s0007114510004381 · Cited by 5
Nauck, M. A., Schmidt, W. E., & Meier, J. J. (2007) · Springer eBooks · doi:10.1007/978-0-387-69737-6_12 · Cited by 5
Physiology and Pathophysiology of GLP-1
Göke, B., Göke, R., Fehmann, H. C., & Bode, H. (1996) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-61150-6_17 · Cited by 6
Intestinal Proglucagon-Derived Peptides
Brubaker, P. L., & Drucker, D. J. (1999) · Humana Press eBooks · doi:10.1007/978-1-59259-695-9_20 · Cited by 7
Brodersen, K., Mose, M., Ramer Mikkelsen, U., Jørgensen, J. O. L., Festersen Nielsen, M., Møller, N., Wegeberg, A., Brock, C., Hartmann, B., Holst, J. J., et al. (2022) · Physiological Reports · doi:10.14814/phy2.15462 · Cited by 4
“Gastric acid secretion is inhibited by GLP- 1, which is in line with our findings of significantly higher median small bowel pH and a larger pH rise from the stomach to the small bowel during SI (Wettergren et al., 1993).”
BackgroundResultSelf-citationRaman Microscopy Investigation of GLP-1 Peptide Association with Supported Phospholipid Bilayers
Bryce, D. A., Kitt, J. P., & Harris, J. M. (2021) · Langmuir · doi:10.1021/acs.langmuir.1c01663 · Cited by 4
Incretin physiology and its role in type 2 diabetes mellitus.
Svec, F. (2010) · PubMed · Cited by 6
Jensen, P. B., Larsen, P. J., Karlsen, C., Jensen, H. I., Holst, J. J., & Madsen, O. D. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01439.x · Cited by 4
Self-citationTorun, A. N., & Ertuğrul, D. T. (2015) · InTech eBooks · doi:10.5772/59241 · Cited by 4
Incretins and Regulation of Insulin Secretion
Nauck, M. A., & Meier, J. J. (2008) · Springer eBooks · doi:10.1007/978-4-431-75452-7_17 · Cited by 4
Chronic pancreatitis and diabetes mellitus: a review of the literature
Lomakina, E. Y., Таратина, О. В., & Александровна, Б. Е. (2019) · Almanac of Clinical Medicine · doi:10.18786/2072-0505-2019-47-075 · Cited by 4
Treatment Strategies for Type 2 Diabetes Based on Incretin Action
Gallwitz, B., & Nauck, M. A. (2007) · CRC Press eBooks · doi:10.3109/9780849379581-13 · Cited by 5
A surface plasmon resonance assay for characterisation and epitope mapping of anti‐GLP‐1 antibodies
Thomsen, L., & Gurevich, L. (2018) · Journal of Molecular Recognition · doi:10.1002/jmr.2711 · Cited by 4
Gastrointestinal Peptide Hormones Regulating Energy and Glucose Homeostasis
Drucker, D. J. (2006) · Elsevier eBooks · doi:10.1016/b978-012088394-3/50009-x · Cited by 5
Glucagon and Glucagon‐like Peptide Production and Degradation
Kieffer, T. J., Hussain, M. A., & Habener, J. F. (2001) · Comprehensive physiology · doi:10.1002/cphy.cp070208 · Cited by 5
Glucagon-Like Peptide-1 and Diabetes 2012
Monami, M., Pasquale, G. D., Rowzee, A. M., Rotella, C. M., & Mannucci, E. (2012) · Experimental Diabetes Research · doi:10.1155/2012/768760 · Cited by 5
Böhm, E. W., Omran, W., Zadeh, J. K., Arad, T., Pfeiffer, N., Patzak, A. R., Oelze, M. W., Daiber, A., Helmstädter, J., Steven, S., et al. (2025) · Experimental Eye Research · doi:10.1016/j.exer.2025.110562 · Cited by 4
Krogh, L. S. L., Helsted, M. M., Englund, A., Bergmann, N. C., Skov‐Jeppesen, K., Nielsen, C. K., Hansen, C. P., ROSENKILDE, M. M., Hartmann, B., Holst, J. J., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70186 · Cited by 3
Self-citationTanaka, M., & Itoh, H. (2025) · International Summit on Diabetes, Endocrinology and Metabolic Disorders · doi:10.1038/s41440-025-02418-2 · Cited by 3
Liraglutide prevents body and fat mass gain in ovariectomized Wistar rats
Rossetti, C. L., Andrade, I. S., Boa, L. F. F., Neves, M. B., Fassarella, L. B., Bertasso, I. M., de Souza, M. D. G. C., Bouskela, E., Lisboa, P. C., Takyia, C. M., et al. (2024) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2024.112374 · Cited by 3
Holst, J. J. (2024) · The Journal of Physiology · doi:10.1113/jp287461 · Cited by 5
Self-citationIdentification of glucagon like peptide-1 (GLP-1) in mice stomach
Otsuka, M., Huang, J., Tanaka, T., & Sakata, I. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.149708 · Cited by 3
Andersen, E. S., Lund, A., Bagger, J. I., Andreasen, C. H., Grøndahl, M. F. G., Deacon, C. F., Hartmann, B., Holst, J. J., Knop, F. K., & Vilsbøll, T. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13321 · Cited by 4
Self-citationThe Role of Incretins in Insulin Secretion
Schroeder, B. E., & Kolterman, O. (2009) · Springer eBooks · doi:10.1007/978-0-387-09841-8_4 · Cited by 3
Byrne, M. M., & Göke, B. (1997) · Frontiers in diabetes · doi:10.1159/000194739 · Cited by 4
Absorption of the cholic acid‐conjugated peptide hormone cholylsecretin from the rat ileum in vivo
McHarg, S., Morton, J. S., McGinn, B., Yasin, M., & Morrison, J. D. (2004) · Acta Physiologica Scandinavica · doi:10.1111/j.1365-201x.2004.01272.x · Cited by 3
Sandoval, D. A., Gong, B., & Davis, S. N. (2007) · Metabolism · doi:10.1016/j.metabol.2007.06.031 · Cited by 3
Las incretinas como nuevas dianas terapéuticas de la diabetes tipo 2
Puig‐Domingo, M., & Reviriego, J. (2007) · Revista Clínica Española · doi:10.1157/13107949 · Cited by 4
Dipeptidyl peptidase IV inhibitors for type 2 diabetes and metabolic syndrome
Wiedeman, P. E., & Trevillyan, J. M. (2005) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2005.05.020 · Cited by 4
Potential of GLP-1 in Diabetes Management
Holst, J. J., Nauck, M. A., Deacon, C. F., & Ørskov, C. (1996) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-61150-6_18 · Cited by 3
Self-citationWilliams, J. A. (2014) · doi:10.3998/panc.2014.7 · Cited by 4
Higgins, V., & Adeli, K. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65897-x · Cited by 3
From the Discovery of GLP-1 to Today’s Diabetes/Obesity Therapy and Beyond
Holst, J. J. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2026.04.010 · Cited by 3
Self-citationLee, J. J., Bajgain, P., & Lightner, A. L. (2026) · Frontiers in Gastroenterology · doi:10.3389/fgstr.2026.1790420 · Cited by 3
El GLP-1: acción biológica y posibles efectos terapéuticos
Valverde, I., Cancelas, J., & Villanueva-Peñacarrillo, M. (2006) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(06)71100-7 · Cited by 6
Israelitisches Krankenhaus in Hamburg
Lehrkrankenhaus, A. (2014) · Cited by 2
Kanoshima, K., Matsuura, M., Kaai, M., Inoh, Y., Ohkuma, K., Iida, H., Nonaka, T., Fujita, K., Ida, T., Kusakabe, A., et al. (2017) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.16-100 · Cited by 4
Novel Modified GLP-1 Derivatives with Prolonged Glucose-Lowering Ability In Vivo
Liu, Y., Wang, Q., Nie, D., Zhang, Y., Wang, Z., & Zhang, Y. (2019) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-019-09991-4 · Cited by 2
GIP und GLP-1-Rezeptoragonismus in der Therapie des Typ 2 Diabetes mit Fokus auf Tirzepatid
Nauck, M. A., Blüher, M., Meyhöfer, S. M., Heitmann, E., & Görgens, S. W. (2023) · Diabetologie und Stoffwechsel · doi:10.1055/a-2102-2436 · Cited by 3
Incretin therapy in feline diabetes mellitus – A review of the current state of research
Haller, N., & Lutz, T. A. (2024) · Domestic Animal Endocrinology · doi:10.1016/j.domaniend.2024.106869 · Cited by 4
Gilannejad, N., Murashita, K., Habte‐Tsion, H., Tolås, I., Verri, T., & Rønnestad, I. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-90873-3.00005-1 · Cited by 8
Diabetes Mellitus and Dyspepsia
Duvnjak, L. S. (2011) · Springer eBooks · doi:10.1007/978-1-4419-1730-0_18 · Cited by 2
Bode, B. W., & Amin, A. (2009) · Hospital Practice · doi:10.3810/hp.2009.12.249 · Cited by 2
Begley, J., Bowes, A., Hart, T., Zouwail, S., & Kerr, D. E. (2013) · journal of Diabetes Research and Clinical Metabolism · doi:10.7243/2050-0866-2-10 · Cited by 2
Translating Clinical Trial Data Into New Patterns of Practice
Peragallo‐Dittko, V. (2009) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721708330154 · Cited by 2
Coming of Age for the Incretins
Holst, J. J., & Deacon, C. F. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-572-5_14 · Cited by 2
Self-citationGlucagon and the Glucagon-Like Peptides
Drucker, D. J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00034-2 · Cited by 2
Çakmak, R., Çaklılı, Ö. T., Tekin, S., Hacışahinoğulları, H., Tanrıkulu, S., Koc, M. S., & Dınççağ, N. (2021) · Biomarkers in Medicine · doi:10.2217/bmm-2021-0318 · Cited by 2
L’internista ospedaliero nella gestione del paziente diabetico complesso
Magnani, G. E. L., Beltramello, G., Brancato, D., Fontanella, A., & Nardi, R. (2018) · Italian Journal of Medicine · doi:10.4081/itjm.q.2018.2 · Cited by 2
Targeting Enteroendocrine Cells to Treat Metabolic Disease
Roberts, A. G., Phuah, P., Cheng, S., & Murphy, K. G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00068-2 · Cited by 3
GÓRSKA, A., & Arciszewski, M. B. (2020) · Medycyna Weterynaryjna · doi:10.21521/mw.6374 · Cited by 3
Design of the Entero-Insular Axis
Creutzfeld, W. (1997) · Frontiers in diabetes · doi:10.1159/000194725 · Cited by 3
Liraglutide, a GLP‐1 Analogue to Treat Diabetes
Knudsen, L. B. (2010) · Wiley eBooks · doi:10.1002/9783527630035.ch14 · Cited by 2
Edmondson, S. D., & Kim, D. (2008) · Methods and principles in medicinal chemistry · doi:10.1002/9783527621460.ch17 · Cited by 2
Non‐Insulin Parenteral Therapies
Holst, J. J., Madsbad, S., & Schmitz, O. (2010) · Wiley eBooks · doi:10.1002/9781444324808.ch30 · Cited by 4
Self-citationGhosh, K., & Sobhia, M. E. (2022) · Research Square · doi:10.21203/rs.3.rs-1721735/v1 · Cited by 2
Gao, L., Shao, Q., Zhuo, X., Xu, Y., & Zhang, Y. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1783385 · Cited by 1
Chapter 14 Role of the intestine in regulation of food intake in growing pigs
Gregory, P. C. (2002) · Biology of growing animals · doi:10.1016/s1877-1823(09)70130-4 · Cited by 1
Fujishima, Y., & Maeda, N. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-407869-7.00015-5 · Cited by 1
The Role of Central Nervous System Glucagon-Like Peptide-1 in the Regulation of Energy Balance
Barrera, J. G. (2009) · OhioLink ETD Center (Ohio Library and Information Network) · Cited by 1
Glucose: Physiological Norm and Pathology
Denisova, T. P., & Malinova, L. I. (2008) · Series in medical physics and biomedical engineering · doi:10.1201/9781584889755.ch1 · Cited by 4
Morgan, L. (2005) · CRC Press eBooks · doi:10.1201/9781420038798.ch2 · Cited by 1
Glucagon-like Peptide-1 Analogue and Dipeptidyl Peptidase-IV Inhibitors
Oh, S. (2006) · Journal of Korean Endocrine Society · doi:10.3803/jkes.2006.21.6.437 · Cited by 1
Incretin physiology in health and disease
Meier, J. J., & Nauck, M. A. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch11 · Cited by 1
Normal Insulin Secretion in Humans
Utzschneider, K. M., Porte, D., & Kahn, S. E. (2003) · Wiley eBooks · doi:10.1002/0470862092.d0205 · Cited by 1
Sierra-Ascencio, M. E., Ríos-Vaca, A., & Reza‐Albarrán, A. (2006) · PubMed · Cited by 1
Shestakova, M. V., & Vikulova, O. K. (2007) · Diabetes Mellitus · doi:10.14341/2072-0351-5908 · Cited by 1
Sesti, G. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01072.x · Cited by 1
Pharmacological Regulation of Postprandial Gastrointestinal Motility by Glucagon in Conscious Dogs.
Shimatani, T. (1997) · Journal of Smooth Muscle Research · doi:10.1540/jsmr.33.187 · Cited by 1
Gastric emptying in humans; carbohydrate ingestion, gastrointestinal hormones and genetic variation
Yau, M. W. A. (2026) · e-space (Manchester Metropolitan University) · doi:10.83056/mmu.32435778 · Cited by 1
Morgan, L. (2005) · CRC Press eBooks · doi:10.1201/9781420038798-3 · Cited by 1
The GIuco-Incretin Hormone Glucagon-Like Peptide-1 and Its β-Cell Receptor
Thorens, B. (1994) · Humana Press eBooks · doi:10.1007/978-1-4612-0241-7_15 · Cited by 2
Gastrointestinal signals regulating appetite in humans
Oesch, S. (2005) · edoc (University of Basel) · doi:10.5451/unibas-003768417 · Cited by 1
Extrapancreatic Action of GLP-1
Göke, B. (1997) · Frontiers in diabetes · doi:10.1159/000194738
In vivo Regulation of Human Islet Hormone Secretion by Glucagon-Like Peptide-1
D’Alessio, D. A., & Ensinck, J. W. (1997) · Frontiers in diabetes · doi:10.1159/000194733
Effects of GLP-1 on Gastric Acid and Pancreatic Exocrine Secretion and on Gastrointestinal Motility
Nauck, M. A., Schepp, W., Holst, J. J., & Schmiegel, W. (1997) · Frontiers in diabetes · doi:10.1159/000194736
Self-citation糖尿病の治療戦略として期待されるglucagon-like peptide-1 (GLP-1)
立石, カ. (1999) · 臨床化学 · doi:10.14921/jscc1971b.28.4_167
[GLP-1 derivatives, for the prevention and treatment of type 2 diabetes mellitus].
難波, 光., 宮川, 潤., & Hamaguchi, T. (2005) · PubMed
Glycaemic Response in Relation to Gastric Emptying and Satiety in Health and Disease
Hlebowicz, J. (2008) · Lund University Publications (Lund University) · Cited by 2
Zetu, C., Munteanu, R., Frunză, A., & Ionescu-Tirgoviste, C. (2012) · Romanian Journal of Diabetes Nutrition and Metabolic Diseases · doi:10.2478/v10255-012-0049-6
Metadata
- Authors
- Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J.
- Affiliations
- University of Copenhagen (DK)
- Venue
- Digestive Diseases and Sciences
- Published
- 1993-04
- Volume
- 38
- Issue
- 4
- Pages
- 665-673
- ISSN
- 0163-2116 (ISSN-L)
- 1573-2568
- OpenAlex
- W2087063469
- Cited by
- 670
- References
- 39
- Citations by year
- 2026: 12 · 2025: 10 · 2024: 20 · 2023: 9 · 2022: 14 · 2021: 22 · 2020: 10 · 2019: 19 · 2018: 17 · 2017: 18 · 2016: 23 · 2015: 27 · 2014: 25 · 2013: 21 · 2012: 25
- FWCI
- 7.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Digestive Diseases and Sciences (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- gastric acid secretion, gastric emptying, postprandial insulin secretion, glucagon secretion, blood glucose, gastrin, incretins
- MeSH terms
- Adult, Depression, Chemical, Female, Gastric Acid, Gastric Emptying, Gastric Mucosa, Glucagon, Humans, Infusions, Intravenous, Lipase, Male, Pancreas, Peptide Fragments, Protein Precursors, Random Allocation, Reference Values, Time Factors, Trypsin, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.